CZ2003199A3 - Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici - Google Patents

Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici Download PDF

Info

Publication number
CZ2003199A3
CZ2003199A3 CZ2003199A CZ2003199A CZ2003199A3 CZ 2003199 A3 CZ2003199 A3 CZ 2003199A3 CZ 2003199 A CZ2003199 A CZ 2003199A CZ 2003199 A CZ2003199 A CZ 2003199A CZ 2003199 A3 CZ2003199 A3 CZ 2003199A3
Authority
CZ
Czechia
Prior art keywords
dosage form
stomach
therapeutic agent
release
gastric
Prior art date
Application number
CZ2003199A
Other languages
Czech (cs)
English (en)
Inventor
Vered Rosenberger
Moshe Fleshner-Barak
E. Itzhak Lerner
Mazal Dahan
Yisrael Imakov
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of CZ2003199A3 publication Critical patent/CZ2003199A3/cs

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
CZ2003199A 2000-06-23 2001-06-22 Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici CZ2003199A3 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04

Publications (1)

Publication Number Publication Date
CZ2003199A3 true CZ2003199A3 (cs) 2003-12-17

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2003199A CZ2003199A3 (cs) 2000-06-23 2001-06-22 Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici

Country Status (11)

Country Link
EP (1) EP1305021A4 (enExample)
JP (1) JP2004501190A (enExample)
KR (1) KR20030013460A (enExample)
AU (2) AU6872201A (enExample)
CA (1) CA2412490A1 (enExample)
CZ (1) CZ2003199A3 (enExample)
EA (1) EA200300046A1 (enExample)
HU (1) HUP0301465A3 (enExample)
IL (1) IL153497A0 (enExample)
MX (1) MXPA02012793A (enExample)
WO (1) WO2002000213A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
JP2005501097A (ja) * 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー 膨張可能な胃内滞留装置
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
JP2007509146A (ja) * 2003-10-20 2007-04-12 テバ ファーマシューティカル インダストリーズ リミティド レボドーパの持続効果のための組成物及び投与形
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
RU2007143510A (ru) 2005-04-27 2009-06-10 Яллал МЕССАДЕК (BE) Инсулиновые композиции
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
JPWO2008087882A1 (ja) 2007-01-15 2010-05-06 キッセイ薬品工業株式会社 胃内滞留型レボドパ徐放性製剤
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
EP2306823A4 (en) 2008-06-30 2012-09-26 Tocagen Inc 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
ES2740360T3 (es) * 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
JP2012508228A (ja) * 2008-11-07 2012-04-05 サムヤン コーポレイション メチルフェニデートの放出制御用薬剤学的組成物
EP2661262B1 (en) * 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
WO2015083171A1 (en) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
EP3261625B1 (en) * 2015-02-27 2024-08-14 Cingulate Therapeutics LLC Tripulse release stimulant formulations
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
DK3609472T3 (da) 2018-06-18 2021-04-06 Kashiv Specialty Pharmaceuticals Llc Forlænget frigivelsessammensætning indeholdende pyridostigmin
JP7034343B2 (ja) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー 自己調節性の浸透性胃保持性薬物送達システム
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
EP3968980A1 (en) * 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020264092A1 (en) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
WO2021176361A1 (en) 2020-03-02 2021-09-10 Craft Health Pte Ltd Method of manufacturing oral dosage forms for extended drug release
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
GB202414411D0 (en) * 2024-10-01 2024-11-13 King S College London Hydrogel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
JP2001510788A (ja) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド 薬学的薬剤を薬学的に口腔内に制御放出するためのタンニン酸ポリマー組成物

Also Published As

Publication number Publication date
MXPA02012793A (es) 2004-07-30
AU6872201A (en) 2002-01-08
IL153497A0 (en) 2003-07-06
AU2001268722B8 (en) 2005-09-29
HUP0301465A2 (hu) 2004-05-28
CA2412490A1 (en) 2002-01-03
JP2004501190A (ja) 2004-01-15
EA200300046A1 (ru) 2003-10-30
EP1305021A1 (en) 2003-05-02
EP1305021A4 (en) 2009-09-23
KR20030013460A (ko) 2003-02-14
AU2001268722B2 (en) 2005-08-11
WO2002000213A1 (en) 2002-01-03
HUP0301465A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2001268722B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
AU2001268722A1 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
RU2385712C2 (ru) Рецептура с контролируемым высвобождением
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6749867B2 (en) Delivery system for omeprazole and its salts
Kotreka et al. Gastroretentive floating drug-delivery systems: a critical review
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
Singh et al. Pulsatile drug delivery system: an approach of medication according to circadian rhythm
WO2007106960A1 (en) Controlled-release floating dosage forms
US20170231927A1 (en) Pharmaceutical compositions of memantine
WO1998027967A1 (en) Release-controlled coated tablets
KR100531065B1 (ko) 활성제 방출이 제어된 의약 제제
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
JP2008540437A (ja) キニーネを含有する制御放出調合剤
US20180008558A1 (en) Extended release compositions of an aminoalkyl nitrate
CN107961225A (zh) 一种普瑞巴林微孔渗透泵片及其制备方法
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
Katakam et al. Floating drug delivery systems: a review